Renal Cell Carcinoma CPG Mini Module - Management of Toxicities

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.   

Virginia Seery, MSN, RN, ANP-BC, AOCNP - Beth Israel Deaconess Medical Center presents practical information on the management of toxicities associated with VEGF or mTOR inihibitor monotherapy, nivolumab monotherapy, and combination therapies.  Symptoms and management of skin and liver toxicities and hand foot syndrome are of particular focus.  Ms. Seery emphasizes the importance of a multi-disciplinary approach in managing toxicities with RCC therapies and provides insights on when to hold or continue immunotherapy if a patient exhibits adverse events associated with RCC treatment.  This mini module ends with a panel discussion of patient tolerance of TKIs and how individual patient tolerances may necessitate changes to TKI therapy regimens. 

Run time: 9 minutes 48 seconds

Target Audience 

Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists. 

SITC Online Education Disclaimer 

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021). 
 
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.